What are the most effective topical treatments for hidradenitis suppurativa?

Best Topical Treatments for Hidradenitis Suppurativa

Topical clindamycin 1% solution is the only evidence-based topical antibiotic for HS, effective at reducing pustules in mild-to-moderate disease (Hurley stage I-II), though it does not improve inflammatory nodules or abscesses and carries significant risk of inducing Staphylococcus aureus resistance. 1

Primary Topical Recommendations

Topical Clindamycin 1% Solution

• Use for: Hurley stage I or II disease with predominantly pustular lesions
• Evidence: A 12-week RCT of 27 patients demonstrated significant pustule reduction and improved patient self-assessment, though inflammatory nodules and abscesses were unaffected 1, 2
• Dosing: Applied twice daily for at least 12 weeks
• Critical caveat: Increases antibiotic resistance rates in HS patients 1
• Risk mitigation: Combine with benzoyl peroxide wash to reduce resistance development 1

Antiseptic Cleansers (Expert Opinion-Based)

The North American guidelines support daily use of antibacterial washes, though no specific agent has been studied in controlled trials 1:

• Chlorhexidine
• Benzoyl peroxide
• Zinc pyrithione

These are recommended as foundational adjunctive therapy for all patients regardless of disease severity.

Resorcinol 15% Cream

• Use for: Hurley stage I-II disease, particularly during acute flares
• Evidence: Small study (n=12) showed reduced pain and abscess duration when used twice daily during flares and daily between flares 1
• Major limitation: Frequent irritant contact dermatitis limits tolerability 1
• Clinical positioning: Consider as second-line keratolytic option when clindamycin fails or resistance is a concern

Intralesional Therapy

Intralesional Triamcinolone

• Use for: Individual inflamed lesions during acute flares
• Dosing: 10 mg/mL (0.2-2.0 mL per lesion) 1
• Evidence: Prospective case series demonstrated significant reduction in erythema, edema, suppuration, and lesion size, with pain improvement within 24 hours 1
• British guidelines rating: Strength of recommendation ↑ (consider for carefully selected individual lesions) 2
• Practical application: Best reserved for isolated, acutely inflamed nodules requiring rapid symptom control; not suitable for widespread disease

Emerging Topical Options

Topical Ruxolitinib (JAK Inhibitor)

• Status: Investigational, not yet approved
• Evidence: Early trials in mild-to-moderate HS show encouraging HiSCR response rates with favorable safety profile and histologic reduction in epidermal/dermal inflammation 3
• Clinical relevance: May represent future first-line option for mild disease, addressing the current gap in approved therapies for early-stage HS

Treatment Algorithm for Topical Therapy

For Hurley Stage I (isolated nodules/abscesses, no scarring):

1. Start antibacterial cleanser (chlorhexidine or benzoyl peroxide) daily
2. Add topical clindamycin 1% twice daily for 12 weeks
3. If pustules persist: Continue clindamycin with benzoyl peroxide wash to prevent resistance
4. For acute inflamed nodules: Add intralesional triamcinolone 10 mg/mL

For Hurley Stage II (recurrent lesions with sinus tracts and scarring):

1. Antibacterial cleanser daily (foundational)
2. Topical clindamycin 1% as adjunct only—systemic therapy is required 1
3. Intralesional steroids for select acute lesions
4. Consider resorcinol 15% if tolerability allows

Critical Limitations of Topical Therapy

The North American guidelines explicitly state that topical clindamycin has no effect on inflammatory nodules and abscesses—the hallmark lesions of clinically significant HS 1. This fundamental limitation means:

• Topical therapy alone is insufficient for most patients beyond very mild disease
• Patients with any nodules or abscesses require systemic antibiotics (tetracyclines or clindamycin/rifampin combination) 1, 2
• Moderate-to-severe disease (Hurley II-III) requires systemic therapy ± biologics, with topicals serving only as adjuncts 1

Common Pitfalls to Avoid

1. Monotherapy with topical clindamycin in nodular disease: Will fail because it doesn't address inflammatory nodules 1
2. Prolonged topical clindamycin without benzoyl peroxide: Drives antibiotic resistance 1
3. Expecting topical therapy to prevent progression: No evidence supports disease modification with topicals alone
4. Using isotretinoin topically or systemically: British guidelines give strong recommendation against isotretinoin unless concomitant facial/truncal acne present 2

Quality of Evidence Assessment

The evidence base for topical HS therapy is notably weak 4:

• Only one RCT exists for topical clindamycin (n=27) 1
• Most data comes from case series and expert opinion
• No standardized outcomes across studies
• High risk of bias in most available studies 4

Despite limited evidence, the 2019 North American guidelines provide Level III recommendations (expert consensus) for topical clindamycin and resorcinol, and Level II recommendation for intralesional corticosteroids 1. The British guidelines similarly rate topical clindamycin as ↑ (consider) rather than ↑↑ (offer), reflecting the modest evidence quality 2.

Bottom line: Topical therapy has a narrow role in HS management—primarily for very mild pustular disease or as adjunct to systemic therapy. Most patients require systemic antibiotics, biologics, or surgery for meaningful disease control.